Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of irinotecan + anlotinib for first recurrent high-grade glioma
ChiCTR1900024323Phase 4Not yet recruiting
- Sponsor
- PLA Army Specialty Medical Center
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan and anlotinib in glioma, sponsored by PLA Army Specialty Medical Center. Primary endpoints: 6-month progression-free survival and adverse events. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
irinotecananlotinib
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR1900024323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024323.